TY - JOUR
T1 - An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia
AU - Ahern, Verity
AU - Adeberg, Sebastian
AU - Fossati, Piero
AU - Garrett, Richard
AU - Hoppe, Bradford
AU - Mahajan, Anita
AU - Orlandi, Ester
AU - Orecchia, Roberto
AU - Prokopovich, Dale
AU - Seuntjens, Jan
AU - Thwaites, David
AU - Trifiletti, Daniel
AU - Tsang, Richard
AU - Tsuji, Hiroshi
N1 - Funding Information:
Stephanie Rossi, Stephen Spedding, Emma Clarke
Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/10
Y1 - 2023/10
N2 - BACKGROUND AND PURPOSE: To establish the treatment indications and potential patient numbers for carbon ion radiation therapy (CIRT) at the proposed national carbon ion (and proton) therapy facility in the Westmead precinct, New South Wales (NSW), Australia.METHODS: An expert panel was convened, including representatives of four operational and two proposed international carbon ion facilities, as well as NSW-based CIRT stakeholders. They met virtually to consider CIRT available evidence and experience. Information regarding Japanese CIRT was provided pre- and post- the virtual meeting. Published information for South Korea was included in discussions.RESULTS: There was jurisdictional variation in the tumours treated by CIRT due to differing incidences of some tumours, referral patterns, differences in decisions regarding which tumours to prioritise, CIRT resources available and funding arrangements. The greatest level of consensus was reached that CIRT in Australia can be justified currently for patients with adenoid cystic carcinomas and mucosal melanomas of the head and neck, hepatocellular cancer and liver metastases, base of skull meningiomas, chordomas and chondrosarcomas. Almost 1,400 Australian patients annually meet the consensus-derived indications now.CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.
AB - BACKGROUND AND PURPOSE: To establish the treatment indications and potential patient numbers for carbon ion radiation therapy (CIRT) at the proposed national carbon ion (and proton) therapy facility in the Westmead precinct, New South Wales (NSW), Australia.METHODS: An expert panel was convened, including representatives of four operational and two proposed international carbon ion facilities, as well as NSW-based CIRT stakeholders. They met virtually to consider CIRT available evidence and experience. Information regarding Japanese CIRT was provided pre- and post- the virtual meeting. Published information for South Korea was included in discussions.RESULTS: There was jurisdictional variation in the tumours treated by CIRT due to differing incidences of some tumours, referral patterns, differences in decisions regarding which tumours to prioritise, CIRT resources available and funding arrangements. The greatest level of consensus was reached that CIRT in Australia can be justified currently for patients with adenoid cystic carcinomas and mucosal melanomas of the head and neck, hepatocellular cancer and liver metastases, base of skull meningiomas, chordomas and chondrosarcomas. Almost 1,400 Australian patients annually meet the consensus-derived indications now.CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.
UR - http://www.scopus.com/inward/record.url?scp=85166575794&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2023.109816
DO - 10.1016/j.radonc.2023.109816
M3 - Journal article
C2 - 37480996
SN - 0167-8140
VL - 187
SP - 109816
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109816
ER -